Dafna Capital Management LLC Biocryst Pharmaceuticals Inc Transaction History
Dafna Capital Management LLC
- $390 Million
- Q2 2024
A detailed history of Dafna Capital Management LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Dafna Capital Management LLC holds 704,500 shares of BCRX stock, worth $5.94 Million. This represents 1.12% of its overall portfolio holdings.
Number of Shares
704,500
Previous 709,500
0.7%
Holding current value
$5.94 Million
Previous $3.6 Million
20.78%
% of portfolio
1.12%
Previous 0.87%
Shares
19 transactions
Others Institutions Holding BCRX
# of Institutions
257Shares Held
173MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$168 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$158 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$106 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$78.8 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$74.4 Million4.25% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.57B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...